Jeffrey Martin, MD
Ophthalmology · Smithtown, NYNPI 1437160579
Payments from drug & device makers
Across 533 payments — averaging $478.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$100K
- Bausch & Lomb Americas Inc.$42K
- Ocular Therapeutix, Inc.$31K
- Oyster Point Pharma, Inc.$29K
- Rxsight Inc$15K
- Kala Pharmaceuticals, Inc.$8K
- plus $30K from 23 others
What the payments were for
- Consulting fees$91,61837%
- Speaking & faculty fees$125,00651%
- Travel & lodging$10,2874%
- Food & beverage$20,2698%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 155 | $99,995 |
| Bausch & Lomb Americas Inc. | 62 | $41,528 |
| Ocular Therapeutix, Inc. | 42 | $31,321 |
| Oyster Point Pharma, Inc. | 59 | $29,238 |
| Rxsight Inc | 25 | $15,077 |
| Kala Pharmaceuticals, Inc. | 24 | $8,036 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $6,974 |
| Shire North American Group Inc | 17 | $6,520 |
| Glaukos Corporation | 13 | $6,103 |
| Rayner Intraocular Lenses Limited | 2 | $3,366 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $2,670 |
| AbbVie(2 entities) | 59 | $1,558 |
| Alcon Research LLC | 2 | $676 |
| NEW World Medical,inc. | 2 | $443 |
| Harrow Eye, LLC | 8 | $331 |
| Amgen | 5 | $311 |
| Novartis | 17 | $270 |
| Ivantis, Inc | 1 | $149 |
| Sun Pharmaceutical Industries Inc. | 7 | $136 |
| Carl Zeiss Meditec USA, Inc. | 1 | $134 |
| Johnson & Johnson Vision Care, Inc. | 1 | $120 |
| Tarsus Pharmaceuticals, Inc. | 2 | $68 |
| Eyevance Pharmaceuticals LLC | 4 | $61 |
| Dompe US, Inc. | 3 | $60 |
| Biotissue Holdings Inc. | 2 | $49 |
| Sight Sciences, Inc. | 2 | $27 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $23 |
| Beaver-visitec International, Inc. | 1 | $20 |
| Kerr Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$59,800
- AcrySof IQ PanOptix UV IOL$44,599
- XIIDRA$41,756
- MIEBO$40,567
- AcrySof IQ VIVITY$33,077
- DEXTENZA$31,268
- TYRVAYA$20,530
- RXSIGHT CONTACT LENS$14,696
- RXSIGHT INJECTOR CARTRIDGE$14,696
- RXSIGHT INJECTOR HANDPIECE$14,696
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$14,696
- LIGHT ADJUSTABLE LENS (LAL)$11,078
- AcrySof IQ VIVITY IOL$10,275
- ARGOS$9,818
- EYSUVIS$7,615
- TRYPTYR$5,650
- LOTEMAX$4,570
- iStent inject W$3,640
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$3,618
- OMIDRIA$3,350
How this compares
$255,281 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 163 | $221,587 |
| XiidraLifitegrast | 96 | $135,354 |
| Cyclosporine | 95 | $64,408 |
| Bromfenac Sodium | 513 | $50,773 |
| ProlensaBromfenac Sodium | 137 | $46,998 |
| IlevroNepafenac | 114 | $41,040 |
| MoxifloxacinMoxifloxacin Hcl | 1,160 | $23,137 |
| Prednisolone Acetate | 790 | $20,691 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $13,874 |
| TyrvayaVarenicline Tartrate | 15 | $13,567 |
| Loteprednol Etabonate | 92 | $13,449 |
| LumiganBimatoprost | 25 | $13,401 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $8,195 |
| Latanoprost | 421 | $5,405 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 144 | $4,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,558 | $243,184207 claims |
| Bausch & Lomb Americas Inc.Xiidra | $41,528 | $135,35496 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $6,974 | $60,447229 claims |
| NovartisIlevro | $270 | $41,040114 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $29,238 | $13,56715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Smithtown
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.